Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

BTN2A, a New Immune-Checkpoint Targeting Vg9Vd2 T Cell Cytotoxicity

Carla E Cano, PhD, Christine Pasero, Aude De Gassart, René Hoet, Emmanuel Scotet, Erwan Mortier, Agnes Quemeneur, Chirine Rafia, Antoine Briantais, Anne-Charlotte Le Floch, MBBS,MSc, Daniel Olive, MD PhD

Blood (2019) 134 (Supplement_1): 1044.

https://doi.org/10.1182/blood-2019-128658

Published: 2019

Journal Articles

Family Studies of Whim Syndrome

David C. Dale, MD, Emily Dick, BA, Merideth L. Kelley, MSc, Vahagn Makaryan, MD, Jim Connelly, MD, Audrey Anna Bolyard, RN, BS

Blood (2019) 134 (Supplement_1): 215.

https://doi.org/10.1182/blood-2019-126234

Published: 2019

Journal Articles

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Blood (2019) 134 (Supplement_1): 494.

https://doi.org/10.1182/blood-2019-123674

Published: 2019

Journal Articles

Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Neil L Berinstein, MD, Isabelle Bence-Bruckler, MD, Pierre Laneuville, MD FRCPC, Douglas A. Stewart, MD, Nicholas Allen Forward, MDMSc,FRCPC, Liam Smyth, MDFRCPath, Gail Klein, MSc, Nancy Pennell, BSc, Kim Roos, BA, BSc

Blood (2019) 134 (Supplement_1): 3236.

https://doi.org/10.1182/blood-2019-125963

Published: 2019

Journal Articles

Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Deborah M. Stephens, Hongli Li, MS, Heiko Schoder, MD, David J. Straus, MD, Craig H. Moskowitz, MD, Michael L. Leblanc, PhD, Lisa M. Rimsza, MD, Nancy L. Bartlett, MD, Andrew M. Evens, DO, MSc, Ann S. LaCasce, MD MSc, Paul Barr, MD, Michael V. Knopp, Eric D. Hsi, MD, John P. Leonard, MD, Brad S Kahl, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2018) 132 (Supplement 1): 929.

https://doi.org/10.1182/blood-2018-99-113034

Published: 2018

Journal Articles

Regression of Epithelial Cancers Following T Cell Receptor Gene Therapy Targeting Human Papillomavirus-16 E7

Scott Michael Norberg, DO, Nisha Nagarsheth, PhD, Stacey Doran, MD, Jennifer A Kanakry, MD, Sabina Adhikary, PhD, Colleen Schweitzer, PhD, Stephanie H Astrow, PhD, William Faquin, MD, Nikolaos Gkitsas, Steven Highfill, PhD, Christian S Hinrichs

Blood (2018) 132 (Supplement 1): 492.

https://doi.org/10.1182/blood-2018-99-117017

Published: 2018

Journal Articles

A Twenty Years Epidemiology Study of 2 nd Hematological Malignancies Post to the Initial Tumor Treatment: Report from Southern China Single Cancer Group

Siliang Chen, Zheyuan Qin, Stephen Liang, MD

Blood (2018) 132 (Supplement 1): 5903.

https://doi.org/10.1182/blood-2018-99-118481

Published: 2018

Journal Articles

Engineering of CD19-Specific Chimeric Antigen Receptor T Cells with the Integrin CD103 Results in Augmented Therapeutic Efficacy Against Human Lymphoma in a Preclinical Model

Hongxing Sun, PhD, Shan He, PhD, Lijun Meng, PhD, Ying Wang, PhD, Hanghang Zhang, PhD, Yongnian Liu, Jian Wang, MD, Min Tao, MD, Stefan Klaus Barta, MD MRCP, MS, Essel D. Al-Saleem, MD, Henry C. Fung, FRCP, MBBChir, Jean-Pierre Issa, MD, Leizhen Zheng, MD, Yi Zhang, MD

Blood (2018) 132 (Supplement 1): 2050.

https://doi.org/10.1182/blood-2018-99-117354

Published: 2018

Journal Articles

Impact of Prior Cancer on Eligibility for Plasma Cell Disorder (PCD) Clinical Trials

Sandra Garcia, Olivia Dorsey, MSIS, Sandi Pruitt, PhD MPH, Saurabh Dahiya, MD, David Gerber, MD, Robert Frank Cornell, MD, Daniel Auclair, PhD, Robert H. Collins, MD, Steven Devine, Saad Z. Usmani, MD, Larry Anderson, MD PhD, Shaji K. Kumar, MD, Ankit Kansagra, MD

Blood (2018) 132 (Supplement 1): 2267.

https://doi.org/10.1182/blood-2018-99-113510

Published: 2018

Journal Articles

No Excess Risk of Second Malignancies in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs)

Lilian Iglesias, Sudipto Mukherjee, MD PhD MPH, Aziz Nazha, MD, Anjali S. Advani, MD, Aaron T. Gerds, MDMS, Hetty E. Carraway, MD MBA, Matt Kalaycio, MD, Jaroslaw P. Maciejewski, PhD MD FACP, Navneet S. Majhail, MD MS, Mikkael A. Sekeres, MD MS

Blood (2017) 130 (Supplement 1): 2872.

https://doi.org/10.1182/blood.V130.Suppl_1.2872.2872

Published: 2017

Journal Articles

Human Papillomavirus (HPV)--Specific T-Cells Can be Generated from Unimmunized Donors for Third Party Cell Therapy of HPV-Associated Neoplasms

Conrad Russell Young Cruz, MD PhD, Sarah McCormack, BA, Kaylor Elizabeth Wright, BS, Allison B Powell, BS, Haili Lang, MS, Cecilia Barese, MDPhD, Connie Trimble, MD, Michael Keller, MD, Ephraim J. Fuchs, MD MBA, Catherine M. Bollard, MD FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 1923.

https://doi.org/10.1182/blood.V130.Suppl_1.1923.1923

Published: 2017

Journal Articles

Analysis of Outcome of Patients Treated with Anti PD-1/Pdl-1 Therapy According to the Degree of Lymphopenia

Sarbajit Mukherjee, MD, Michael Machiorlatti, Bilal Khalid, MD, Gabriel Souza Vidal, MD, Jennifer Holter Charkrabarty, MD, Mohamad A. Cherry, MDMS

Blood (2017) 130 (Supplement 1): 3594.

https://doi.org/10.1182/blood.V130.Suppl_1.3594.3594

Published: 2017

Journal Articles

p21-Associated Kinase 4 (PAK4) Addiction in Multiple Myeloma: A Potential Therapeutic Application with Enhanced Activity in FGFR3 Expressing Myeloma

Mariateresa Fulciniti, PhD, Joaquin Martinez Lopez, MD PhD, William Senapedis, PhD, Stefania Oliva, MD, Raphaël Szalat, MD, Mehmet K. Samur, PhD, Rao H Prabhala, PhD, Kenneth C. Anderson, MD, Nikhil C Munshi, MD

Blood (2016) 128 (22): 3302.

https://doi.org/10.1182/blood.V128.22.3302.3302

Published: 2016

Journal Articles

A Novel NKp44-Based Chimeric Antigen Receptor That Targets Multiple Types of Cancer

Yasushi Kasahara, MD, Changsu Shin, MD, Sakiko Yoshida, MD PhD, Takayuki Takachi, MD PhD, Nobuhiro Kubo, MD, Haruko Iwabuchi, MD PhD, Masaru Imamura, MD PhD, Akihiko Saitoh, MD PhD, Chihaya Imai, MD PhD

Blood (2016) 128 (22): 3517.

https://doi.org/10.1182/blood.V128.22.3517.3517

Published: 2016

Journal Articles

Clinical Heterogeneity in RUNX1-Associated Familial Myelodysplastic Syndrome - Report of Two Novel Pedigrees with Childhoodleukemia

Tim Ripperger, Birgit Burkhardt, PhD MD, Fabian Hauck, MD PhD, Michael H. Albert, MD, Kathrin Thomay, Dr. rer. nat., Marcin Wlodarski, MD, Ayami Yoshimi, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, Prof, MD, Charlotte M Niemeyer, Prof, MD, Doris Steinemann, Prof

Blood (2016) 128 (22): 5509.

https://doi.org/10.1182/blood.V128.22.5509.5509

Published: 2016

Journal Articles

ITP or Not-ITP - a Rare Case of PTLD Recurrence Presenting As Autoimmune Thrombocytopenia

Vikas Kumar Singh, MD, Margaret Means, Danh Pham, MD, Goetz H Kloecker, MD

Blood (2016) 128 (22): 4942.

https://doi.org/10.1182/blood.V128.22.4942.4942

Published: 2016

Journal Articles

ANP32A Regulates Histone 3 Acetylation and Promotes Leukemogenesis in AML

Xuejing Yang, Xueqin Sun, PhD, Bin Lu, PhD, Qianfei Wang, PhD, Zan Huang, PhD

Blood (2016) 128 (22): 3917.

https://doi.org/10.1182/blood.V128.22.3917.3917

Published: 2016

Journal Articles

Risk for New Malignancies of Potential Infectious Etiology Among Adult Survivors of Specific Non-Hodgkin Lymphoma Subtypes

Megan M Herr, PhD, Sara J. Schonfeld, PhD, Graca M. Dores, MD MPH, Margaret A. Tucker, MD, Rochelle E Curtis, MA, Lindsay M Morton, PhD

Blood (2016) 128 (22): 2414.

https://doi.org/10.1182/blood.V128.22.2414.2414

Published: 2016

Journal Articles

Prevalence and Risk Predictive Factors of Comorbid Malignancies in Patients with Chronic Myeloid Leukemia

Tong-Yoon Kim, MD, Sung-Eun Lee, Soo-Hyun Kim, Soo-Young Choi, Eun-Jung Jang, Dong-Wook Kim, MD PhD

Blood (2016) 128 (22): 1900.

https://doi.org/10.1182/blood.V128.22.1900.1900

Published: 2016

Journal Articles

Standardized Long-Term Follow-up after Allogeneic Stem Cell Transplantation: A Cross-Sectional 1-Year Evaluation in 260 Adults

Blood (2015) 126 (23): 4362.

https://doi.org/10.1182/blood.V126.23.4362.4362

Published: 2015

NARROW

BTN2A, a New Immune-Checkpoint Targeting Vg9Vd2 T Cell Cytotoxicity

Family Studies of Whim Syndrome

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Regression of Epithelial Cancers Following T Cell Receptor Gene Therapy Targeting Human Papillomavirus-16 E7

A Twenty Years Epidemiology Study of 2 nd Hematological Malignancies Post to the Initial Tumor Treatment: Report from Southern China Single Cancer Group

Engineering of CD19-Specific Chimeric Antigen Receptor T Cells with the Integrin CD103 Results in Augmented Therapeutic Efficacy Against Human Lymphoma in a Preclinical Model

Impact of Prior Cancer on Eligibility for Plasma Cell Disorder (PCD) Clinical Trials

No Excess Risk of Second Malignancies in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs)

Human Papillomavirus (HPV)--Specific T-Cells Can be Generated from Unimmunized Donors for Third Party Cell Therapy of HPV-Associated Neoplasms

Analysis of Outcome of Patients Treated with Anti PD-1/Pdl-1 Therapy According to the Degree of Lymphopenia

p21-Associated Kinase 4 (PAK4) Addiction in Multiple Myeloma: A Potential Therapeutic Application with Enhanced Activity in FGFR3 Expressing Myeloma

A Novel NKp44-Based Chimeric Antigen Receptor That Targets Multiple Types of Cancer

Clinical Heterogeneity in RUNX1-Associated Familial Myelodysplastic Syndrome - Report of Two Novel Pedigrees with Childhoodleukemia

ITP or Not-ITP - a Rare Case of PTLD Recurrence Presenting As Autoimmune Thrombocytopenia

ANP32A Regulates Histone 3 Acetylation and Promotes Leukemogenesis in AML

Risk for New Malignancies of Potential Infectious Etiology Among Adult Survivors of Specific Non-Hodgkin Lymphoma Subtypes

Prevalence and Risk Predictive Factors of Comorbid Malignancies in Patients with Chronic Myeloid Leukemia

Standardized Long-Term Follow-up after Allogeneic Stem Cell Transplantation: A Cross-Sectional 1-Year Evaluation in 260 Adults

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only